Navigation Links
Intracellular in Biological Technology

Novel compound may treat acute diarrhea

... toxins that bring about elevations of a group of intracellular messengers, cyclic nucleotides, that stimulate ... ability of several bacterial toxins to elevate intracellular levels of cyclic nucleotides, and inhibits fluid ... are responsible for increasing the production of intracellular messenger molecules. These molecules contribute ...

Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.

... for Lipid and Polypeptide Based siRNA intracellular Delivery -- Compositions and Methods for ... Cations -- Cationic Peptides for siRNA intracellular Delivery -- Formulations for intracellular Delivery dsRNA -- Compositions and Methods ...

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452

... increase cardiac cell contractility by increasing the concentration of intracellular calcium, which further activates the cardiac sarcomere. This effect on ... myosin activators have been shown to work in the absence of changes in intracellular calcium by a novel mechanism that directly stimulates the activity of the ...

LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit

... cell metabolism, cell proliferation, cell death (apoptosis) and cell invasion. HIF-1 alpha protein is low in normal cells, but reaches high intracellular concentrations in a variety of cancers and is strongly correlated with poor prognosis and resistance to therapy. Enzon is currently conducting two ...

Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

... 2009 3:30pm Clinical novel oxazolidinone, is Relevance active against intracellular S. aureus, L. monocytogenes and L. pneumophila phagocytosed ...

Rigel Announces First Quarter 2009 Financial Results

... develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with ...

Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator

... to improve survival, reduce bacterial infections and suppress inflammation. IMX942 is a small, proprietary, fully synthetic peptide that binds to an intracellular adaptor protein and modifies the signaling network downstream of TLR, TNF, and IL-1 receptors. IMX942 has no direct anti-bacterial activity but can ...

Rigel to Present at Citi's Biotech Day

... develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with ...

Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions

... of HPV-induced lesions. Interferon alpha-2b is thought to function by triggering an antiviral response within infected cells, by activating certain intracellular enzymes which cause degradation of viral RNA, and by mobilizing the body's natural immune system to destroy the infected cells. Interferon alpha-2b, ...

aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong

... enzymes and reported the first evidence that fragments and splice variants of these proteins have latent extracellular activities distinct from their intracellular roles in protein synthesis. With a wide variety of cell signaling activities, this class of unexplored peptides provides a reservoir of proteins ...

Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia

... enzymes and reported the first evidence that fragments and splice variants of these proteins have latent extracellular activities distinct from their intracellular roles in protein synthesis. With a wide variety of cell signaling activities, this class of unexplored peptides provides a reservoir of proteins ...

Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

... proteins chemically linked at specific sites to phosphates. This profile provides the Company with a proprietary and unique window into the intracellular action of CNS drugs or drug candidates. ITI uses this platform in its drug discovery and development efforts of proprietary compounds and also to ...

InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies

... sequences to DXL antibodies, which facilitate penetration of DXL(TM) antibodies into cancer cells. The ability to direct our DXL(TM) antibodies to intracellular targets by the addition of a membrane transport sequence, imparts great therapeutic potential in a number of applications. The patents and ...

Innovative Biosensors and ProGenTech Partner to Develop a Rapid Diagnostics System

... a calcium sensitive bioluminescent molecule. Cross-linking of the antibodies by even minute amounts of the specific pathogen leads to elevation of intracellular calcium and light emission. The amplified light output can then be detected using a luminometer. ProGenTech has been developing workflow ...

Bert W. O'Malley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovo's Scientific Advisory Board

... activate or inactivate a receptor's ligand binding domain for eventual transcriptional regulation. His work was furthered when he discovered that intracellular coactivator/corepressor ratios determine the tissue specificities of SERMs. Among the awards and honors that Dr. O'Malley has received are the ...

Rigel to Participate at the RBC Capital Markets Healthcare Conference

... drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with ...

Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH

... drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with ...

VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research

... President and Chief Executive Officer of VisualSonics, "We will be enabling researchers to push the limits of discovery as we develop tools for intracellular and molecular imaging with VisualSonics technology and Seno Medical IP." VisualSonics will embed Seno's opto-acoustic technology in their next ...

LI-COR Introduces Three IRDye(R) Near-Infrared Fluorescence Resonance Energy Transfer (NIR-FRET) Protease Substrates

... of the function of Beta-Secretase, it has been established as a validated therapeutic target for Alzheimer's disease. Caspases are a family of intracellular cysteine proteases that are vital in the process of apoptosis (programmed cell death). Caspase-3 functions as the most downstream executioner in the ...

Rigel to Present at the 2008 Credit Suisse Healthcare Conference

... drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with ...

Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent

... company located in Las Vegas, Nevada. The company is dedicated to the engineering, marketing and manufacture of transfection reagents and kits for intracellular and tissue-targeted delivery of biomolecules (http://www.altogen.com ). Altogen Custom Services focus on providing specialized biotechnology and ...

Rigel Announces Third Quarter 2008 Financial Results and Clinical Update

... drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with ...

Rigel to Host Update Conference Call

... drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with ...

Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant

... one of the major ways in which nitric oxide influences heart function is by activating the main calcium channel in the heart to release calcium from intracellular stores. Calcium is the primary determinant of contractility in the heart. A deficiency in nitric oxide disrupts the calcium cycle, inhibits heart ...

Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.

... of his long-term interest in horizontal gene transfer among bacteria, Dr. Courvalin has been a thought leader in the area of using bacteria as intracellular vectors for delivery of DNA or proteins into mammalian cells. His laboratory was the first to describe the combination of invasin and listeriolysin ...

Abeome Forms First Class Scientific Advisory Board

... PhD, Associate Director of the Life Sciences Institute at the University of British Columbia, has a distinguished research career focused on intracellular trafficking and cell signaling of specific membrane receptors on the cell surface of B lymphocytes, the source of antibody production. "We are ...

GlaxoSmithKline and Cellzome Announce Major Strategic Alliance

... We are excited to be working with Cellzome to discover and develop improved approaches to existing biologic therapies which cannot access intracellular signaling mechanisms. Cellzome's Kinobeads(TM) technology will provide a distinct advantage because it uses native kinases directly isolated from ...

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

... This system enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. ...

Silence Therapeutics Patent Update

... This system enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. ...

Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia

... dual mechanism of action. CTA018 is designed to be a strong activator of the vitamin D signaling pathway as well as a potent inhibitor of CYP24, the intracellular enzyme responsible for catabolism of vitamin D hormones. Based on its mechanism of action, CTA018 is expected to be more effective in treating SHPT ...

Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027

... This system enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. ...

Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008

... clinical responses correlated with downregulation of R2, the cellular target of LOR- 2040, and were further supported by demonstration of intracellular LOR-2040 in circulating and bone marrow leukemic cells. - Signed an exclusive multinational license agreement with Zor Pharmaceuticals ...

Organizational Changes at Silence Therapeutics

... This system enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. ...

Silence Therapeutics Announces Successful Opposition of Glover Patent

... This system enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. ...

SpectraCell Laboratories Now Measures Vitamin C

... -- Effective immediately, SpectraCell Laboratories now measures functional levels of Vitamin C (ascorbate) using its proprietary FIA(TM) (Functional intracellular Analysis) technology. This test enables a clinician to diagnose specific vitamin and mineral deficiencies long before classic deficiency symptoms ...

Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)

... Notably, the study population included unfavourable patients with at least one adverse prognostic characteristic. The clinical study also measured intracellular uptake of LOR-2040 in the bone marrow leukemic cells, and identified significant accumulation of the drug in the bone marrow blast cells and ...

FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry

... This system enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. ...

GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections

... that expel toxins such as antibiotics that have permeated the outer cell membrane before they can reach their targets and kill the bacteria. Higher intracellular antibiotic concentrations achieved through efflux pump inhibition can increase the potency and pharmacological barrier against other drug resistance ...

Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting

... Histone Deacetylase Inhibitors and Cell Cycle Inhibitors Poster presentation: PCI-24781, a novel hydroxamic acid HDAC inhibitor, raises intracellular levels of reactive oxygen species, induces apoptosis and inhibits NFkB in leukemia models Abstract #741: 8:00 a.m. - 12:00 p.m. ...

Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery

... system, AtuPLEX. This enables the delivery of siRNA molecules to targeted diseased tissues and cells, whilst increasing their bioavailability and intracellular uptake. In July 2007, Silence Therapeutics formed a research and development collaboration with AstraZeneca to develop AtuRNAi against five ...
Other Contents
(Date:7/23/2014)... BCC Research ( ... MARKETS AND TECHNOLOGIES FOR SENSORS , the global market ... to nearly $154.4 billion by 2020, with a five-year ... flow, and level sensors segment is moving at a ... ) , Sensors have become indispensable to ...
(Date:7/23/2014)... MINNETONKA, Minn. , July 23, 2014 /PRNewswire/ ... technology company specializing in clinical study management systems, ... West , a proven life sciences industry executive ... named Chief Operating Officer (COO).  Clareece will be ... and sales growth, operational efficiency and quality product/service ...
(Date:7/23/2014)... of getting tangled and forming knots. Scientists study these ... disentangle them (e.g. useful for gene sequencing techniques). Cristian ... (SISSA) in Trieste and his team have been carrying ... their dynamics. In their latest paper, just published in ... Marco Di Stefano, first author and PhD student at ...
Breaking Biology News(10 mins):Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3MedNet Appoints Clareece West As Chief Operating Officer 2
(Date:7/23/2014)... MA (PRWEB) July 23, 2014 ... technologies, the leasing and financing company LeaseQ announced ... the server based software sector, they still see ... , To learn more about technology equipment ... Founder and CEO of LeaseQ was quoted as ...
(Date:7/23/2014)... 23, 2014 According to a new ... Form Factor (Integrated Circuit IP, SOC IP), Design Architecture ... Geography and Verification IP - Forecast & Analysis to ... expected to grow at a CAGR of 12.6% from ... , Browse more than 76 market data tables with ...
(Date:7/23/2014)... Splashtop , a leader ... it has joined the RSA Ready Technology Partner ... and RSA SecurID® multi-factor authentication solution from RSA, ... , Splashtop also announced that leading Japanese Insurance ... Enterprise, the industry’s only on-premise remote access solution. ...
(Date:7/23/2014)... The Centers for Disease Control and Prevention ... from 2010 to 2012. Formerly known as “the nation’s ... access to some of the strongest opiates, such as Oxycontin, ... enforcement launched an initiative to crack down on these rampant ... 65 that existed in the state just a few years ...
(Date:7/23/2014)... first time to call for better screening of psoriatic ... the condition. , Psoriatic arthritis (PsA) causes painful joint ... untreated. , PsA tends to affect people with the ... and affects approximately two per cent of people in ... on to develop PsA usually within ten years ...
Breaking Medicine News(10 mins):Health News:LeaseQ Announces That Although Software Investment Remains Sluggish, Technology Equipment Leasing Demand Remains Robust 2Health News:LeaseQ Announces That Although Software Investment Remains Sluggish, Technology Equipment Leasing Demand Remains Robust 3Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Splashtop Joins RSA® Ready Technology Partner Program; Announces Adoption by Leading Japan Insurance Group Nissei Asset Management 2Health News:Splashtop Joins RSA® Ready Technology Partner Program; Announces Adoption by Leading Japan Insurance Group Nissei Asset Management 3Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 2Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 3Health News:Florida’s Crackdown on Pill Mills Has Led to Rise in Popularity of Synthetic Drugs; Suncoast Rehab Educates on Dangers of These Drugs in Adolescents 4Health News:Psoriatic arthritis patients need better screening, warns panel of experts 2
Other TagsOther Tags